Scilex Holding Co
Scilex is a biopharmaceutical company that acquires, develops and commercializes non-opioid pain management products for patients with acute and chronic pain. Its commercial products are ZTlido, a prescription lidocaine topical system for neuropathic pain associated with postherpetic neuralgia; ELYXYB, an oral solution for acute migraine in adults; and GLOPERBA, a liquid oral colchicine medication for gout in adults. Its product candidates include SEMDEXA for sciatica, SP-103 for acute pain and SP-104 for fibromyalgia. Scilex also holds an exclusive worldwide license to develop and commercialize KDS2010 in metabolic and neurodegenerative diseases. Scilex markets its products through commercial and distribution operations, including a direct network serving wholesalers and pharmacies throughout the United States. It licenses or acquires rights to products and technologies, and develops product candidates for potential commercialization. The company also plans to hold cryptocurrency as a principal treasury asset and pursue staking and related yield-generating activities. Scilex is headquartered in Palo Alto, California.
No enriched coverage for $SCLX in the last 7 days.
No SEC Form 4 filings for $SCLX in the last 30 days.
See all $SCLX insider activity →DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies ● Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastruc
DataMEDS AI (NASDAQ:MEDS) announced a non-binding LOI with Datavault AI (NASDAQ:DVLT), others, to acquire QOLPOM IP and expand its healthcare ecosystem. The deal aims to integrate health tracking, prescription delivery, and AI/blockchain tech, with a Q4 2026 target close. FDA guidance supports the optimization of DataMEDS' Health Lives Here app. The transaction is subject to due diligence and regulatory approvals.
Scilex Holding Co (SCLX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on August 8, 2026, Scilex Holding Company (the “Company”) entered into a Promissory Note (Revolving Line of Credit) (the “Note”) with Vivasor, Inc. (“Vivasor”), as borrower, pursuant to which the Comp
Recent SCLX coverage spans corporate actions, mergers & acquisitions and crypto.
Neutral to mildly positive as Scilex gains licensing royalties but no direct cash component disclosed.
Neutral to modestly positive as Scilex stands to receive consideration for its IP.
The increased credit line gives Scilex more financing flexibility, which may be viewed positively by investors.
The 8-K adds financing optionality via an uncommitted revolving note, but it is not a guaranteed funding event.
The filing indicates SCLX is repurchasing its preferred shares from Vivasor entities, with consideration paid partly in DVLT shares across multiple tranches.
AlphAI scores every news story that mentions SCLX with an AI model for sentiment and relevance, and aggregates insider trades from Scilex Holding Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies ● Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastruc
DataMEDS AI (NASDAQ:MEDS) announced a non-binding LOI with Datavault AI (NASDAQ:DVLT), others, to acquire QOLPOM IP and expand its healthcare ecosystem. The deal aims to integrate health tracking, prescription delivery, and AI/blockchain tech, with a Q4 2026 target close. FDA guidance supports the optimization of DataMEDS' Health Lives Here app. The transaction is subject to due diligence and regulatory approvals.
Scilex Holding Co (SCLX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on August 8, 2026, Scilex Holding Company (the “Company”) entered into a Promissory Note (Revolving Line of Credit) (the “Note”) with Vivasor, Inc. (“Vivasor”), as borrower, pursuant to which the Comp
Scilex Holding Co (SCLX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2026 (the “Effective Date”), Scilex Holding Company (the “Company”) entered into a Promissory Note (Revolving Line of Credit) (the “Note”) with Vivasor, Inc. (“Vivasor”), as borrower, pursuant to which the Compan
Scilex Holding Co (SCLX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 2 sclx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Stock repurchase AGREEMENT This Stock Repurchase Agreement (this “ Agreement ”) is made and entered into effective as of July 18, 2026 (the “ Effective Date ”) by and among (i) Vivasor Holding Company, a Delaware corporation
Scilex Holding (NASDAQ:SCLX) shares rose about 7% after it said it signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based iHolding Group LLP. iHolding would buy ~6.7 million newly issued shares at $15.00 each. The funding would support expansion, product development, commercialization, acquisitions, and working capital; the deal is subject to closing conditions and approvals.
Scilex Holding Company (Nasdaq: SCLX) said Dream Bowl I Meme Coin tokens began trading on the Biconomy Exchange on July 6, 2026. The company reported it holds about 180 million Dream Bowl Tokens after the April 30, 2026 record-date distribution to eligible holders. Scilex expects trading to improve liquidity and distribution.
U.S. stock index futures rose premarket as investors returned from a holiday. Scilex Holding gained 7% on a binding term sheet for a proposed $100M strategic investment. Vera Therapeutics rose 6% ahead of a July 7 FDA PDUFA decision for atacicept. Solaris Energy Infrastructure rose 3.9% after Wolfe Research coverage and a ~$55M acquisition. Strategy rose 3.4% after adopting a framework to selectively monetize up to $1.25B in Bitcoin holdings.
Scilex Holding (NASDAQ:SCLX) shares rose after the company announced a binding term sheet for a proposed $100M strategic investment from iHolding Group LLP. iHolding would buy newly issued SCLX shares at $15.00 per share (~6.7M shares). The deal is subject to due diligence, definitive agreements, approvals, and regulatory/stockholder consent.
Scilex Holding Company (Nasdaq: SCLX) said it signed a binding term sheet for iHolding Group LLP to invest $100 million by purchasing newly issued Scilex shares at $15.00 per share (~6.67 million shares). Proceeds would support growth, product development, commercialization, acquisitions, working capital, and IP. Closing depends on due diligence, definitive agreements, board and stockholder approvals, and regulatory approvals.
